Divi Rao L, Beland Frederick A, Fu Peter P, Von Tungeln Linda S, Schoket Bernadette, Camara Johanna Eltz, Ghei Monica, Rothman Nathaniel, Sinha Rashmi, Poirier Miriam C
National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA.
Carcinogenesis. 2002 Dec;23(12):2043-9. doi: 10.1093/carcin/23.12.2043.
A chemiluminescence immunoassay (CIA) utilizing antiserum elicited against DNA modified with (+/-)-7beta, 8alpha-dihydroxy-9alpha,10alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]- pyrene (BPDE) has been developed and validated to study the formation of polycyclic aromatic hydrocarbon (PAH)-DNA adducts in human tissues. Advantages include a low limit of detection for 10b-(deoxyguanosin-N(2)-yl)-7beta,8alpha,9alpha-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPdG, approximately 1.5 adducts/10(9) nucleotides using 20 micro g DNA) and a high signal-to-noise ratio (> or =100). The CIA BPDE-DNA standard curve gave 50% inhibition at 0.60 +/- 0.08 fmol BPdG (mean +/- SE, n = 30), which was a 10-fold increase in sensitivity compared with the dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). Calf thymus DNA modified with [1,3-(3)H]BPDE was assayed by radiolabeling, (32)P-postlabeling, DELFIA and CIA, and all assays gave similar values. Liver DNAs from mice exposed to 0.5 and 1.0 mg [7,8-(3)H]benzo[a]pyrene (BP) were assayed by the same four assays and a dose-response was obtained with all assays. The BPDE-DNA CIA was further validated in MCL-5 cells exposed to 4 micro M BP for 24 h, where nuclear and mitochondrial DNA adduct levels were associated with an increase in DNA tail length measured by the Comet assay. Human peripheral blood cell (buffy coat) DNA samples (n = 43) obtained from 25 individuals who were either colorectal adenocarcinoma patients or controls were assayed by BPDE-DNA CIA. Three samples (7%) were non-detectable, and the remaining 40 samples had values between 0.71 and 2.21 PAH-DNA adducts/10(8) nucleotides. The intra-assay coefficient of variation (CV), for four wells on the same microtiter plate, was 1.85%. Sufficient DNA for two assays, on separate plates, was available for 38 of the 43 samples, and the PAH-DNA adduct values obtained were highly correlated (r(2) = 0.95). Coded duplicate DNA samples from 15 individuals were assayed four times gave an inter-assay CV of 13.8%.
已开发并验证了一种化学发光免疫分析(CIA)方法,该方法利用针对用(±)-7β,8α-二羟基-9α,10α-环氧-7,8,9,10-四氢苯并[a]芘(BPDE)修饰的DNA产生的抗血清,以研究人体组织中多环芳烃(PAH)-DNA加合物的形成。其优点包括对10b-(脱氧鸟苷-N(2)-基)-7β,8α,9α-三羟基-7,8,9,10-四氢苯并[a]芘(BPdG,使用20μg DNA时约为1.5个加合物/10⁹个核苷酸)的检测限低,以及信噪比高(≥100)。CIA BPDE-DNA标准曲线在0.60±0.08 fmol BPdG时产生50%抑制(平均值±标准误,n = 30),与解离增强镧系元素荧光免疫分析(DELFIA)相比,灵敏度提高了10倍。用[1,3-(³H)]BPDE修饰的小牛胸腺DNA通过放射性标记、³²P后标记、DELFIA和CIA进行检测,所有检测方法得到的值相似。对暴露于0.5和1.0mg [7,8-(³H)]苯并[a]芘(BP)的小鼠肝脏DNA,用相同的四种检测方法进行检测,所有检测方法均获得了剂量反应。BPDE-DNA CIA在暴露于4μM BP 24小时的MCL-5细胞中进一步验证,其中核和线粒体DNA加合物水平与彗星试验测量的DNA尾长增加相关。对从25名结直肠癌患者或对照个体获得的43份人外周血细胞(血沉棕黄层)DNA样本,采用BPDE-DNA CIA进行检测。3份样本(7%)未检测到,其余40份样本的值在0.71至2.21个PAH-DNA加合物/10⁸个核苷酸之间。同一微量滴定板上四个孔的批内变异系数(CV)为1.85%。43份样本中的38份有足够的DNA用于在单独的板上进行两次检测,获得的PAH-DNA加合物值高度相关(r² = 0.95)。对15名个体的编码重复DNA样本进行四次检测,批间CV为13.8%。